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Thymidine phosphorylase/platelet-derived endothelial cell growth factor
expression associated with hepatic metastasis in gastric carcinoma
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Summary It is known that angiogenesis plays an important role in the growth and metastasis of solid
tumours. Several angiogenic factors have been identified and platelet-derived endothelial cell growth factor
(PD-ECGF) is thought to be one such factor. Recently, it was reported that thymidine phosphorylase
(dThdPase) is identical to PD-ECGF. Using immunohistochemical staining with an anti-dThdPase antibody,
we investigated the correlation between dThdPase expression and the microvessel density in 120 gastric
carcinomas. The microvessel density, determined by immunostaining for factor VIII-related antigen, was
significantly higher in dThdPase-positive tumours than in dThdPase-negative tumours. There was a significant
correlation between dThdPase expression and the increment of microvessel density. Moreover, regarding
distant organ metastasis, the frequency of hepatic metastasis was significantly higher (P<0.01) in patients with
dThdPase-positive tumours than in those with dThdPase-negative tumours. In summary, it was suggested that
dThdPase expression is closely associated with the promotion of angiogenesis and hepatic metastasis in gastric
carcinoma.
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Solid tumours require neovascularisation for growth and
metastasis (Folkman, 1990). It is also thought that the degree
of tumour angiogenesis is related to clinical outcome,
suggesting that angiogenic properties are correlated with
tumour aggressiveness (Bosari et al., 1992; Weidner et al.,
1992; Gasparini et al., 1994). In a previous study (Maeda et
al., 1995) we also demonstrated that the microvessel count is
an independent prognostic indicator in patients with gastric
carcinoma.
Many investigators have demonstrated that tumour cell
secretion and activation of various endothelial growth
factors, termed angiogenic factors, play crucial roles in the
formation of the neovasculature (Ishikawa et al., 1989;
Zagzag et al., 1990; Toi et al., 1994). However, there have
been few studies on the correlation between the expression of
angiogenic factors and progression of malignant tumours.
Recently, it was reported that thymidine phosphorylase
(dThdPase) is identical to platelet-derived endothelial cell
growth factor (PD-ECGF), which is thought to be an
angiogenic factor (Ishikawa et al., 1989; Furukawa et al.,
1992; Haraguchi et al., 1994).
In this study we investigated the correlation between
dThdPase expression and gastric cancer progression by an
immunohistochemical study using an anti-dThdPase mono-
clonal antibody.
Materials and methods
Clinical material
Resected specimens from 120 patients with gastric carcinoma
who underwent gastrectomy at our institution were studied.
The patients ranged in age from 40 to 81 years (average age
59.4 years); 87 were men and 33 were women (Table I). No
patient had received chemotherapy or radiation therapy
before surgery. All patients were followed up at least 5
years after surgery. Throughout this report, the General
Rules for Gastric Cancer were used for the pathological
diagnosis and classification of variables (Japanese Research
Society for Gastric Cancer, 1981). Tumours were divided into
two histological subgroups; differentiated type, which
consisted of papillary and tubular adenocarcinomas and
undifferentiated type, which included poorly differentiated
adenocarcinomas, signet ring cell carcinomas and mucinous
adenocarcinomas. Eighty-seven patients underwent curative
resection and 33 patients underwent non-curative surgical
procedures. Among the 87 patients who underwent curative
resection, 30 experienced disease recurrence. Regarding
distant organ metastasis, 15 patients had synchronous and
six had metachronous hepatic metastases. Peritoneal metas-
tases were observed in 20 patients at the time of surgery and
metachronous peritoneal metastases were observed in 11
patients.
Specimens were fixed in a 10% formaldehyde solution and
embedded in paraffin. Sections (4 um thick) were cut and
mounted on glass slides.
Immunohistochemical determination of thymidine
phosphorylase
Anti-dThdPase mouse monoclonal antibody 654-1 (Nishida
et al., 1994) was obtained from the Nippon Roche Research
Center (Kanagawa, Japan). This antibody was prepared by
using as an antigen human dThdPase purified from human
colon cancer xenograft HCT1 16. The characterisation of this
antibody was reported by Nishida et al. (1994). Immunohis-
Table I Patients' characteristics
Age (years) 40-82
(Mean) (59.5)
Sex
Male 87
Female 33
Stage
I 32
II 13
III 34
IV 14
Operation
Curative 87
Non-curative 33
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November 1995tochemical studies were performed by the streptavidin-biotin
method. Sections were dewaxed in xylene, taken through
ethanol and then incubated with 0.3% hydrogen peroxide in
methanol for 30 min to block endogenous peroxidase
activity. Sections were then washed in phosphate-buffered
saline (PBS) and incubated in 10% normal rabbit serum for
20 min to reduce non-specific antibody binding. Specimens
were then incubated with a 1:200 dilution of 654-1 overnight
at 4°C, followed by three washes with PBS. Sections were
then incubated with biotinylated goat anti-mouse immuno-
globulin G (IgG: Histofine ABC kit; Nichirei Corporation,
Tokyo, Japan) at a dilution of 1:100 for 30 min followed by
three washes. Slides were then treated with streptavidin-
peroxidase reagent (Histofine ABC kit; Nichirei Corporation)
for 30 min at a dilution of 1:100 and were washed with PBS
three times. Finally, slides were incubated in PBS containing
diaminobenzidine and 1% hydrogen peroxide for 10 min,
counterstained with methyl green and mounted. Normal
mouse IgG was substituted for primary antibody as the
negative control. Slides were interpreted for antigen
expression by two investigators without knowledge of the
corresponding clinicopathological data.
The degree of monoclonal antibody reactivity with
individual tissue sections was considered positive if unequi-
vocal staining of cytoplasm or nuclear compartment was seen
in tumour cells, regardless of the number of cells stained.
Microvessel staining and counting
The methods of microvessel staining and counting were as
described previously (Maeda et al., 1995). Briefly, intratu-
moral microvessels were highlighted by immunostaining with
anti-factor VIII-related antigen (F-VIII RAg) monoclonal
antibody (F8/86; Dakopatts, Glostrup, Denmark) in a 1:200
dilution and incubated at room temperature for 2 h. Any
brown stained cell or cluster of endothelial cells, clearly
separate from tumour cells and other connective tissue
elements, was considered as a single vessel. Branching
structures were counted as a single vessel unless there was a
break in the continuity of the structure. The stained sections
were screened at 5 x magnification (using a combination of
1 x objective and 5 x oculars) to identify the areas of the
highest vascular density within the tumour from all tissue
blocks. These high vascularity areas could occur anywhere
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within the tumour but occurred most frequently at the
margins of the carcinoma. Sclerotic areas, where microvessels
were sparse, and areas immediately adjacent to benign tissue
were not considered in vessel counts. Vessels were counted in
the five highest density areas at 200 x magnification (using a
combination of 20 x objective and 10 x ocular, 0.785 mm2
per field). Microvessel count was expressed as the mean
number of vessels in these areas. The counts of both
investigators significantly correlated with each other (by
Spearman rank correlation test; r=0.742, P<0.01), there-
fore, the average of the two investigators' counts was taken
for further analysis.
Statistical methods
Chi-square test or Mann-Whitney U-test were used for the
evaluation of background factors. Survival curves were
calculated using the Kaplan-Meier method and analysed
by the log-rank test. The influence of various clinical and
morphological variables on distant organ metastasis was
considered in a multiple logistic regression analysis.
Furthermore, factors related to survival were analysed by
the Cox's proportional hazard model (Cox, 1972). Statistical
significance was defined as P<0.05.
Results
Normal gastric mucosa was not immunoreactive with anti-
dThdPase antibody. Thymidine phosphorylase was distrib-
uted mainly in the cytoplasm or nuclear compartments of the
carcinoma cells (Figure 1). Tumour cells that stained strongly
for thymidine phosphorylase were more often observed in the
invasive front than in the tumour centre. Moreover, weak
dThdPase expression was sometimes observed in endothelial
cells, lymphocytes or macrophages invaded into tumour
stroma. Thymidine phosphorylase expression was detected
in 73 (60.8%) tumours. Table II shows the correlation
between dThdPase expression and various clinicopathological
factors. There was no significant association between
dThdPase expression, histological type, lymph node metas-
tasis or lymphatic invasion. With respect to depth of invasion
and histological stage, positivity for dThdPase was lower in
more superficial tumours (with mucosal (m) and submucosal
Table II Correlation between expression of thymidine phosphorylase and clinicopathological factors
Expression of thymidine phosphorylase
Variable Number Positive Negative P-value
Histological type
Differentiated n=48 30 (62.5) 18 (37.5) NS
Undifferentiated n=72 43 (59.7) 29 (40.3)
Depth of invasion
m, sm n=27 10 (37.0) 17 (61.0)
pm, ss n=31 22 (71.0) 9 (29.0) NS
se, sei n=62 41 (66.1) 21 (33.9)
Lymph node metastasis
Negative n=42 21 (50.0) 21 (50.0) NS
Positive n=78 52 (66.7) 26 (33.3)
Lymphatic invasion
Negative n=38 16 (42.1) 22 (57.9) NS
Postitive n=82 57 (69.5) 25 (30.5)
Venous invasion
Negative n=47 21 (44.7) 26 (55.3) <0.01
Positive n=73 52 (71.2) 21 (28.8)
Histological stage
I n=32 10 (31.3) 22 (68.7)
II n= 13 12 (92.3) 1 (7.7) NS
III n=34 23 (67.7) 11 (32.3)
IV n=41 28 (68.3) 13 (31.7)
m, mucosal neoplastic involvement; sm, submucosal neoplastic involvement; pm, muscle layer neoplastic involvement; ss, subserosal neoplastic
involvement; se, serosal neoplastic involvement; sei, serosal involvement with directly infiltrating other organs beyond serosaThymidine phosphorylase expression in gastric carcinoma
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(sm) involvement) and stage I tumours, but not at a
significant level. However, a significant difference was noted
with respect to venous invasion by tumour. The dThdPase-
positive rate was significantly higher (P<0.01) in patients
with venous invasion than in those without such invasion.
With regard to the correlation between distant organ
metastasis and dThdPase expression, 15 patients had
synchronous and six had metachronous hepatic metastases
in patients with dThdPase-positive tumours (Table III).
However, neither synchronous nor metachronous hepatic
metastases were observed in patients with dThdPase-negative
tumours. The frequency of hepatic metastasis was signifi-
cantly higher (P<0.05) in patients with dThdPase-positive
tumours than in those with dThdPase-negative tumours,
Figure 1 Immunohistochemical staining for dThdPase in cancer
tissues of the stomach (original magnification x 200). There is a
strong cytoplasmic staining of the tumour cells.
Table III Distant organ metastasis according to the expression of
thymidine phosphorylase
Thymidine phosphorylase status
(%)
Positive Negative
Organ (n = 73) (n =47) P-value
Liver
Synchronous 15 (20.5) 0 (0) <0.01
Metachronous 6 (8.2) 0 (0) <0.05
Total 21 (28.7) 0 (0) <0.01
Peritoneum
Synchronous 8 (11.0) 12 (25.5) NS
Metachronous 6 (8.2) 5 (10.6) NS
Total 14 (18.2) 17 (36.1) NS
whereas there was no significant association between
dThdPase expression and peritoneal metastases. We deter-
mined which factors were related to metachronous hepatic
metastasis by logistic regression analysis: only venous
invasion and dThdPase status were significantly associated
with metachronous hepatic metastasis (Table IV).
Table V shows the correlation between the microvessel
count and dThdPase status. The mean microvessel count in
dThdPase-positive tumours was 22.4+8.5 and was signifi-
cantly higher than in dThdPase-negative tumours (P<0.01,
Mann-Whitney U-test).
The prognosis of the 87 patients who underwent curative
resection was studied. As shown in Figure 2, we found the
prognosis of the patients with dThdPase-positive tumours to
be significantly (P<0.01, by log-rank test) worse than that of
those with dThdPase-negative tumours. The 5 year survival
rate in patients with dThdPase-positive tumours was 50.0%
(24/48), which was significantly lower than the rate in those
with dThdPase-negative tumours (84.6%, 33/39). However,
multivariate analysis using the Cox's model showed that only
Table V Correlation between the expression of dThdPase and
microvessel count
dThdPase status Number Mean +s.d. Median (range)
Positive n=73 22.4+8.5a 21.5 (17.5-50.0)
Negative n=47 14.3+8.8a 12.5 (10.0-30.4)
aMicrovessel count in patients with dThdPase-positive tumours was
significantly higher than in those with dThdPase-negative tumours
(P<0.01, Mann -Whitney U-test). s.d., standard deviation.
1o
C',
5,
0
U 1U zU JU 4U bU DU
Time after surgery (months)
Figure 2 Survival rate after curative resection. Thymidine
phosphorylase-negative (- - -); thymidine phosphorylase-positive
( )-
Table IV Risk factors affecting metachronous hepatic metastasis analysed by multiple logistic regression model
Variables Coefficient s.e. Coefficient/s.e. P-value
dThdPase status
Negative 0.182 0.063 2.908 0.044
Positive
Histological type
Differentiated 0.014 0.070 0.194 0.846
Undifferentiated
Serosal invasion
Negative 0.143 0.074 1.946 0.846
Positive
Lymph node metastasis
Negative 0.011 0.077 0.143 0.8864
Positive
Lymyphatic invasion
Negative 0.131 0.076 0.0880 0.367
Positive
Venous invasion
Negative 0.163 0.071 2.296 0.0235
Positive
s.e., standard errorThymidine phosphorylase expression in gastric carcinoma
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Table VI Risk factors affecting overall survival analysed by Cox's proportional hazard model
Variables Hazard ratio 95% CI P-value
dThdPase status
Negative 1.262 0.891-2.192 0.100
Positive
Histological type
Differentiated 0.881 0.534- 1.355 0.502
Undifferentiated
Serosal invasion
Negative 1.734 0.982-2.886 0.037
Positive
Lymph node metastasis
Negative 1.453 0.723-2.490 0.073
Positive
Lymphatic invasion
Negative 1.102 0.751 -2.135 0.367
Positive
Venous invasion
Negative 1.370 0.611-1.683 0.938
Positive
serosal invasion emerged as an independent prognostic factor
and the expression of dThdPase is not an independent factor
(Table VI).
Discussion
In this study, dThdPase expression was observed in 60.8% of
gastric carcinoma and weak immunoreactivity was found in
the endothelium, lymphocyte or macrophages invaded into
tumour stroma. However, normal gastric mucosa was not
immunoreactive with this antibody. Recently, Miwa et al.
(1987) reported that the activity of dThdPase was markedly
increased in tumour components as compared with normal
tissues in a variety of tumours. Our results appear to be
compatible with these data.
It is now well established that malignant tumours depend
on neovascularisation for their growth and metastasis
(Folkman, 1990). Recently, several angiogenic factors have
been identified and PD-ECGF is thought to be one such
factor (Ishikawa et al., 1989; Furukawa et al., 1992; Toi et
al., 1994). Ishikawa et al. (1989) and Usuki et al. (1992)
reported that PD-ECGF stimulates the growth and
chemotaxis of endothelial cells in vitro and possesses
angiogenic activity in vivo. Moreover, Haraguchi et al.
(1994) reported that dThdPase is identical to PD-ECGF
and also has chemotactic and angiogenic activity. Toi et al.
(1995) reported that dThdPase expression was significantly
correlated with tumour microvessel density in breast cancer.
In this study, we also demonstrated that dThdPase expression
was associated with increment of microvessel density and
microvessel count was significantly higher in dThdPase-
positive tumours than in dThdPase-negative tumours. There-
fore, dThdPase is considered to be an important regulator of
tumour angiogenesis and is thought to induce a vascular
stroma in gastric carcinoma.
Furthermore, the frequency of hepatic metastasis was
significantly higher in patients with dThdPase-positive
tumours than in those with dThdPase-negative tumours.
The finding that neovascularisation is most prominent in
dThdPase-positive tumours suggests that an enhanced
vascular supply reflects an increased risk of metastasis.
Tumour cells rarely shed into the circulation before the
primary tumour is vascularised (Folkman, 1992). It has been
shown that greater numbers of tumour vessels increase the
opportunity for tumour cells to enter the circulation (Liotta
et al., 1976). Moreover, newly formed capillaries have
fragmented basement membranes and are leaky, making
them more penetrable by tumour cells than mature vessels
(Nagy et al., 1989). Therefore, in the hypervascular tumours,
the metastatic process may be enhanced by the 'leaky' nature
of newly formed blood vessels facilitating vascular invasion.
With regard to prognosis, we observed a shorter survival
in patients with dThdPase-positive tumours than in those
with dThdPase-negative tumours, but multivariate analysis
indicated that dThdPase expression is not an independent
prognostic factor. However, when we examined the recur-
rence mode, metachronous hepatic metastases were signifi-
cantly more frequent in patients with dThdPase-positive
tumours. Hepatic metastasis is one of the most important
causes of death in patients with gastric carcinoma. To
improve survival in patients with gastric carcinoma, the
prediction of metachronous hepatic metastasis is therefore
important. Our results suggest that the presence of dThdPase
expression was not strongly associated with clinical outcome,
but was useful in predicting metachronous hepatic metastases
in patients with gastric carcinoma.
5-Fluorouracil (5-FU) is an anti-cancer drug used to treat
a variety of neoplastic diseases, particularly cancers of the
digestive organs. 5'-Deoxy-5-fluorouridine (5'-DFUR) is a
prodrug of 5-FU and is converted to 5-FU by dThdPase
(Ishitsuka et al., 1980; Miwa et al., 1987). Recently, Fujii et
al. (1994) reported that 5'-DFUR is effective in primary
tumour regression and liver metastasis prevention. Such
agents may be effective anti-tumour chemotherapeutic
agents with less toxicity in patients with dThdPase-positive
tumours.
Abbreviations
dThdPase, thymidine phosphorylase; PD-ECGF, platelet-derived
endothelial cell growth factor; F-VIII RAg, factor VIII-related
antigen; m, mucosal neoplastic involvement; sm, submucosal
neoplastic involvement; pm, muscle layer neoplastic involvement;
ss, subserosal neoplastic involvement; se, serosal neoplastic
involvement; sei, serosal involvement with directly infiltrating
other organs beyond serosa.
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